Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Confounding in association studies: month of birth and multiple sclerosis.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Assessment of sphingosine-1-phosphate receptor expression and associated intracellular signaling cascades in primary cells of the human central nervous system.
Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Artielle Immunotherapeutics Announces Positive Results of Phase ! Multiple Sclerosis Trial
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
A genome screen for multiple sclerosis in Italian families.
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome.
Rehabilitation interventions in multiple sclerosis: an overview.
Recommendations for the clinical use of motor evoked potentials in multiple sclerosis.
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.

Pages